34 TESTING
Figure 17: Improvement of KP between T0 (left) and after 4 weeks application of Salinicoccus lysate (right).
showed a positive impact on KP parameters (Table 3). The density of KP was significantly decreased by 10.5% versus a slight increase of the placebo treated KP site (p<0.01). In the same way, KP total perimeter was reduced by 7.5% and this was significant compared to placebo site (p<0.05). The illustration provided by Mountains (Fig 17) shows the KP decrease.
Conclusion Using different tools, we developed several methods to quantify and illustrate keratosis pilaris. The dermatoscopic camera allowed us to illustrate the KP with 2D or 3D pictures. The 2D pictures provided a clear view of the lesions with true colors, while 3D views allowed us to see the volume of lesions. Moreover, thanks to camera calibration, it is possible to quantify redness, dryness and additional 3D parameters such as Sa, Sq, Sz. This quantification remains unfortunately
manual with the necessary selection of each KP lesions, further studies being necessary to improve this issue. The quantification method with
replicas and fringes projection allowed us to calculate interesting parameters such as density, volume, perimeter and surface. After a setup phase, both software AEVA and Mountains can be used for KP quantification and we have assessed this in a clinical study. It was interesting to associate automatic quantification part from AEVA and illustrative 3D representation from Mountains. In conclusion, both fringe projection
and dermatoscopic camera are of interest for sharp evaluation of ingredients acting on keratosis pilaris.
PC References
1 Hwang S, Schwatrz RA. Keratosis pilaris: a common follicular hyperkeratosis. Cutis 2008; 82: 177-180.
2 Kootiratrakarn T, Kampirapap K, Chunasewee
Table 3: Variation of keratosis pilaris after 4 weeks cream application Quantity of KP (20x20mm surface)
Salinicoccus Lysate T0
Mean Sd
Variation vs. T0 (%) Significance vs. Placebo p< 0.01 PERSONAL CARE NORTH AMERICA
23.7 7.6
Placebo
T4w 21.2 73
-10.5% T0
20.9 7.2
T4w 21.5 9.2
-2.9% p< 0.05 March 2020
C. Epidermal barrier in the treatment of keratosis pilaris. Dermatol. Res. Practice 2015; ID205012, 5p.
3 Poskitt L, Wilkinson JD. Natural history of keratosis pilaris. Br. J. Dermatol., 1994; 130: 711-713.
4 Plascencia Gomez A, Vega Memije ME, Torrez Tamayo M, Rodriguez Carreon AA. Skin disorders in overweight and obese patients and their relationship with insulin. Actas Dermosifiliogr. 2014; 105: 178-185.
5 Yosipovitch G, Mevorah B, Mashiach J, Chan YH, David M. High body mass index, dry scale leg skin and atopic conditions are highly associated with keratosis pilaris. Dermatology, 2000 ; 201 : 34-36.
6 Gruber R, Sugarman JL, Crumrine D, Hupe M, et al. Sebaceous gland, hair shaft and epidermal barrier abnormalities in keratosis pilaris with and without filaggrin deficiency. Am. J. Pathol. 2015; 185, 1012-1021.
7 Leong WMS, Aw CWD. Nilotinid-induced keratosis pilaris. Case Rep. Dermatol., 2016; 8: 91-96.
Salinicoccus Lysate T0
106.2 29.1
Total perimeter of KP (mm; 20x20mm surface) Placebo
T4w 98.2 35.7
-7.5% T0
98.9 24.9
T4w 103 45.5
+4.1%
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
